MRK and NTHI Related Headlines
Go Back- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- NeOnc Technologies sets phase 2 dose for brain cancer drug NEO212
- NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m.
MRK and NTHI Related Press Releases
Go Back- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m.
